Your browser doesn't support javascript.
loading
A global research priority agenda to advance public health responses to fatty liver disease.
Lazarus, Jeffrey V; Mark, Henry E; Allen, Alina M; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N; Burra, Patrizia; Castro-Narro, Graciela E; Cortez-Pinto, Helena; Cusi, Kenneth; Dedes, Nikos; Duseja, Ajay; Francque, Sven M; Hagström, Hannes; Huang, Terry T-K; Wajcman, Dana Ivancovsky; Kautz, Achim; Kopka, Christopher J; Krag, Aleksander; Miller, Veronica; Newsome, Philip N; Rinella, Mary E; Romero, Diana; Sarin, Shiv Kumar; Silva, Marcelo; Spearman, C Wendy; Tsochatzis, Emmanuel A; Valenti, Luca; Villota-Rivas, Marcela; Zelber-Sagi, Shira; Schattenberg, Jörn M; Wong, Vincent Wai-Sun; Younossi, Zobair M.
Afiliación
  • Lazarus JV; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA. Electronic address:
  • Mark HE; European Association for the Study of the Liver (EASL), Geneva, Switzerland; Independent Consultant, Nottingham, UK.
  • Allen AM; Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Arab JP; Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada; Department of Ga
  • Carrieri P; Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Marseille, France.
  • Noureddin M; Houston Methodist Hospital, Houston Research Institute, Houston, TX, USA.
  • Alazawi W; Barts Liver Centre, Blizard Institute, Queen Mary University of London, London, UK.
  • Alkhouri N; Fatty Liver Program, Arizona Liver Health, Phoenix, AZ, USA.
  • Alqahtani SA; King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
  • Arrese M; Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Bataller R; Liver Unit, Hospital Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Berg T; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
  • Brennan PN; Division of Hepatology, University of Dundee, Dundee, Scotland, UK.
  • Burra P; Multivisceral Transplant Unit-Gastroenterology, Department of Surgery, Oncology and Gastroenterology at the Padua University Hospital, Padua, Italy.
  • Castro-Narro GE; Department of Hepatology and Transplant, Hospital Médica Sur, Mexico City, Mexico; Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Asociación Latinoamericana para el Estudio del Hígado (ALEH), Santiago, Chile.
  • Cortez-Pinto H; Clinica Universitária de Gastrenterologia, Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Cusi K; Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Florida, Gainesville, FL, USA.
  • Dedes N; Greek Patients Association, Athens, Greece.
  • Duseja A; Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Francque SM; Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium; InflaMed Centre of Excellence, Laboratory for Experimental Medicine and Paediatrics, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wil
  • Hagström H; Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Huang TT; CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA; CUNY Center for Systems and Community Design and NYU-CUNY Prevention Research Center, New York, NY, USA.
  • Wajcman DI; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Kautz A; Kautz 5 gUG, Köln, Germany.
  • Kopka CJ; Independent Researcher, Ponte de Lima, Portugal.
  • Krag A; Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.
  • Miller V; University California Berkeley School of Public Health, Berkeley, CA, USA.
  • Newsome PN; National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK.
  • Rinella ME; Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Romero D; Department of Community Health and Social Sciences, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA.
  • Sarin SK; Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
  • Silva M; Hepatology and Clinical Research Units, Hospital Universitario Austral, Buenos Aires, Argentina.
  • Spearman CW; Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Tsochatzis EA; UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK.
  • Valenti L; Precision Medicine, Biological Resource Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Villota-Rivas M; Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Zelber-Sagi S; School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel; Department of Gastroenterology, Tel Aviv Medical Centre, Tel Aviv, Israel.
  • Schattenberg JM; Metabolic Liver Research Program, I. Department of Medicine, University Medical Centre Mainz, Mainz, Germany.
  • Wong VW; The Chinese University of Hong Kong, Hong Kong, China.
  • Younossi ZM; Center for Liver Disease, Inova, Falls Church, VA, USA.
J Hepatol ; 79(3): 618-634, 2023 09.
Article en En | MEDLINE | ID: mdl-37353401
ABSTRACT
BACKGROUND &

AIMS:

An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community.

METHODS:

Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy.

RESULTS:

The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of 'agree' responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement ('agree' + 'somewhat agree'); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% 'agree'), 13 priorities had <80% 'agree', with greater reliance on 'somewhat agree' to achieve >90% combined agreement.

CONCLUSIONS:

Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. IMPACT AND IMPLICATIONS An estimated 38% of adults and 13% of children and adolescents worldwide have fatty liver disease, making it the most prevalent liver disease in history. Despite substantial scientific progress in the past three decades, the burden continues to grow, with an urgent need to advance understanding of how to prevent, manage, and treat the disease. Through a global consensus process, a multidisciplinary group agreed on 28 research priorities covering a broad range of themes, from disease burden, treatment, and health system responses to awareness and policy. The findings have relevance for clinical and non-clinical researchers as well as funders working on fatty liver disease and non-communicable diseases more broadly, setting out a prioritised, ranked research agenda for turning the tide on this fast-growing public health threat.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Problema de salud: 1_doencas_nao_transmissiveis / 1_doencas_transmissiveis / 2_cobertura_universal / 8_alcohol Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies Límite: Adolescent / Child / Humans Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 8_ODS3_consumo_sustancias_psicoactivas Problema de salud: 1_doencas_nao_transmissiveis / 1_doencas_transmissiveis / 2_cobertura_universal / 8_alcohol Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies Límite: Adolescent / Child / Humans Idioma: En Revista: J Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article
...